| Authors: |
Fa'ak F; Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Haan J; Agendia, Inc. , Irvine, CA, USA., Chmielewski-Stivers N; Agendia, Inc. , Irvine, CA, USA., Menicucci A; Agendia, Inc. , Irvine, CA, USA., Audeh W; Agendia, Inc. , Irvine, CA, USA., Soe PP; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Logman Z; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Ahn S; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., D'Abreo N; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Baum J; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Marks DK; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. douglas.marks@nyulangone.org.; Perlmutter Cancer Center, NYU Long Island School of Medicine, 120 Mineola Blvd, Suite 500, Mineola, NY, 11501, USA. douglas.marks@nyulangone.org. |